Kornimate/medical-research-clean huggingface dataset:
response to anti-hypertensives in pregnant and postpartum patients

Conditions: Hypertension in Pregnancy; Preeclampsia

Summary: in this study, the investigators will evaluate the blood pressure response to nifedipine and labetalol in pregnant and postpartum patients, who present with hypertensive disease in pregnancy with severe range blood pressure defined as greater than 160/110. these anti-hypertensives are first line therapy for management of severe range blood pressures in pregnancy and postpartum by the american congress of obstetricians and gynecologist (acog). in addition at the mount sinai west site, the investigators will also analyze the adrb1 and similar genes involved in beta blockade, genes involved in calcium channel blockade and other genes implicated in blood pressure response among pregnant and postpartum patients receiving labetalol and nifedipine. this analysis will be used to determine if a pharmacogenetic association exists between variant alleles in these receptors in the pregnant and postpartum population.

hypertensive disease in pregnancy is a major cause of maternal morbidity and mortality. this condition is responsible for about 12% of the maternal deaths in the united states. currently, if pregnant patients present with severe hypertension they are either given iv labetalol, iv hydralazine of nifedipine based on individual provider preference. there are few studies in the literature comparing oral nifedipine and iv labetalol with mixed data showing either they are equally effective or a faster time to achieving target blood pressure for patients who received nifedipine. in this study, the investigators will evaluate if there is a difference in time to achieve goal blood pressure in pregnant and postpartum patients who are treated with nifedipine and labetalol for severe range blood pressures defined as greater than 160/110. these anti-hypertensives are first line therapy for management of severe range blood pressures in pregnancy and postpartum by the american congress of obstetricians and gynecologist (acog).

Eligibility criteria:
inclusion criteria: * pregnant patients from 20 weeks to up to 6 weeks postpartum * between the ages of 18-55. * persistent severe range blood pressures (2 readings or more within 15 minutes) of either 160mmhg systolic or 110mmhg diastolic. exclusion criteria: * multiple gestation * patients with non-reassuring fetal heart rate (category 3) * patients with abruptio placenta * patients with renal impairment * history of heart failure * history of cardiac arrhythmia * use of anti-hypertensive medications in the past 24 hours * patients with allergies or medical contraindications to labetalol or nifedipine.

Keywords: hypertension, pregnancy-induced pregnancy induced hypertension gestational hypertension transient hypertension, pregnancy pharmacogenetics
retrospective study in patients with metastatic renal cancer treated with tki sequence (tyrosine kinase inhibitors of vegfr) - mtor- axitinib inhibitors or anti-vegf antibody -inhibiteurs mtor - axitinib

Conditions: Kidney Neoplasms

Summary: describe in patients with metastatic kidney cancer treatment modalities with the type sequences: tki - mtori - axitinib or vegf mab - mtori - axitinib.


Eligibility criteria:
inclusion criteria: * patient with metastatic kidney cancer (all histological types) * male or female aged (e) of 18 or more * patient has been treated or under treatment with axitinib (inlyta®) in the third line after the first line of targeted tki therapy and after mtori in 2nd line, or * patient receiving the treatment sequence vegfmab - mtori - axitinib for living patients: patient informed and having given oral consent exclusion criteria: * patient who received more than one line of antiangiogenic therapy in the metastatic phase before initiation of treatment with axitinib (except patients in the study pisces) patient received a second line treatment with tki patient refused to participate in the study

Keywords: kidney neoplasms kidney neoplasms tki axitinib vegf mtori
the children in action feasibility study

Conditions: Obesity; Motor Activity

Summary: the children in action (cia) program was a five month physical activity intervention. this intervention was a feasibility study with 3- to 5-year-olds enrolled in four head start centers. after baseline assessment, centers were matched by ethnicity and for number of participants and randomly assigned to either the intervention or the control condition. a total of 224 preschool children were randomly selected across the four centers. to evaluate the efficacy of the cia intervention, the change in physical activity, gross motor skills and weight during the awake time and used mixed effect time-series regression models was compared. observations did not show a statistical difference between intervention and control groups in physical activity level during the awake time, gross motor development or weight status. it was demonstrated that it is feasible to conduct the spark-ec curriculum among preschool children attending head start centers but that an increased dose and/or longer intervention duration will be required to impact gross motor skills, weight status and physical activity levels during this critical early childhood development stage.


Eligibility criteria:
inclusion criteria: * 3-5 years old * attends head start * african-american * hispanic-american exclusion criteria: * older than 5 years old * does not attend head start * race/ethnicity other than african-american or hispanic-american * has a disability or handicap that would prevent them from participating in physical activities

Keywords: physical activity children head start spark-ec
computer - based treatment for social anxiety disorder

Conditions: Social Anxiety Disorder

Summary: the present study is a controlled trial that seeks to examine the feasibility, acceptability, mechanism, and efficacy of a recently developed computer-based therapy in individuals with social anxiety disorder (sad)

this randomized clinical trial examines the feasibility, acceptability, mechanism, and relative efficacy of two forms of a recently developed 4-week/8-session computer-based therapy in individuals with social anxiety disorder (sad). the purpose of this study is to assess whether a brief computer-based research treatment, provided in 30 minutes sessions, helps improve social anxiety symptoms, and by what mechanism. the study will also assess the effect of research treatments on brain activity using magnetic resonance imaging (mri).

Eligibility criteria:
inclusion criteria: * males and females between the ages of 18 to 60 * current primary diagnosis of sad * score of at least 50 on the liebowitz social anxiety scale (self-rated version) * fluent in english * willing and able to give informed written consent * ability to participate responsibly in the protocol * normal or corrected-to-normal vision exclusion criteria: * present or past psychotic episode, psychotic disorder, schizophrenia, schizoaffective disorder, or bipolar disorder * current severe depression * suicidal ideation or behavior * current diagnosis of post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder, manic episode or tic disorder * current or past organic mental disorder, seizure disorder, epilepsy or brain injury * current unstable or untreated medical illness * severe alcohol use disorder, severe cannabis use disorder, and any severity of other substance use disorder (except nicotine use disorders) * use of psychiatric medication in the past month other than a stable dose of selective serotonin reuptake inhibitors (ssris) for at least 3 months * any concurrent cognitive behavioral therapy or other psychotherapy that was initiated in the past 3 months * pregnancy, or plans to become pregnant during the period of the study (will be assessed by urine) * contraindication to mri scanning (paramagnetic metallic implants or devices contraindicating magnetic resonance imaging or any other non-removable paramagnetic metal in the body) 1. pacemaker 2. paramagnetic metallic prosthesis 3. surgical clips 4. shrapnel 5. necessity for constant medicinal patch 6. some tattoos * inability to tolerate mri scanning procedures (i.e., severe obesity, claustrophobia)

Keywords: attention
impact of ketoflex 12/3 diet on early-to-mid stage alzheimer's progression

Conditions: Alzheimer Type Dementia; Alzheimer&#39;s Disease (AD)

Summary: this study investigates the effects of the ketoflex 12/3 diet on the clinical progression of early-to-mid stage alzheimer's disease. the study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the ketoflex 12/3 dietary protocol.


Eligibility criteria:
inclusion criteria: * age between 50-85 years * clinical dementia rating (cdr) score of 0.5 or 1 * diagnosis of alzheimer's disease (ad) according to nincds-adrda criteria exclusion criteria: * alcohol and/or substance dependence * diagnosis of chronic renal failure * diagnosis of another neuropsychiatric disorder * presence of amalgam dental fillings and/or failure to have them removed following the smart protocol

Keywords: alzheimer's disease ketogenic diet intermittent fasting ketoflex 12/3 cognitive decline neurodegeneration
evaluation of the role of low dose magnesium sulfate in anesthesia for toxic goiter resection

Conditions: Haemodynamic Stability

Summary: anesthesia for toxic goiter removal is a challenging because of of hemodynamic instability especially during induction, intubation, manipulations of the gland, after removal of the gland and during emergence. so, hemodynamic stability is required all through the operation and even in the first 12 hours of the postoperative period to protect against complications e.g., hypertension, tachycardia, myocardial ischemia, bleeding and thyrotoxic crisis.mg sulphate used in blunting pressor response during laryngoscopy and intubation. also it was used in controlled hypotension technique. also it was reported in decreasing postoperative nausea, vomiting, shivering and postoperative complications compared to controlled group.

patients and methods: after obtaining the approval of the ethical committee number (r68) of al fayoum university hospitals and written informed consent from the patients, sixty (60) patients asa ǀ \&ǁ patients of both sex aging 20-70 years (with primary or secondary thyrotoxic goiter and will be presented for thyroidectomy) will be allocated into one of two groups: group (m) n=30 will receive mg so4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. group (s) n=30 will receive saline in equal volume. the surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. the solution will be prepared by an expert anesthesia nurse.

Eligibility criteria:
inclusion criteria: 1. patients asa ǀ \&ǁ 2. patients of both sex 3. aging from 20-70years 4. pstients with primary or secondary thyrotoxic goiter exclusion criteria: 1. major hepatic disease 2. renal disease. 3. cardiac dysfunction e.g. (heart failure). 4. uncontrolled hypertension 5. advanced ischemic heart diseases. 6. known allergy to mg so4. 7. morbid obesity \& pregnancy. 8. history of neuromuscular diseases. 9. cerebrovascular diseases. 10. diabetic neuropathy. 11. patients receiving magnesium. supplementations. 12. mental retardation 13. patients on antiepileptic treatment 14. patients antipsychotics. 15. hug goiter with retrosternal extension.

Keywords: thyrotoxic goiter heamodynamics magnesium sulphate
impact on functional status in older adults treated with l-carnitine

Conditions: Carnitine; Muscle; Functional Status; Old Age; Debility

Summary: this study evaluates the impact of the treatment with l-carnitine on the function of adults over 65 years, in conjunction with regular exercise. simple randomization will be performed, distributing patients in 3 treatment groups, with l-carnitine or placebo, and with physical exercise at home or supervised.

the supplemental intake of l-carnitine improves the physical functioning of the pre-fragile and fragile elder of the community. circulating l-carnitine levels increase after administration of the supplement. the impact on the function of l-carnitine in combination with physical exercise will be studied in a population of older adults in montevideo. the sample will be divided into 3 groups, according to the intervention: group 1: patients who will receive l-carnitine in addition to a manual to perform physical exercise at home. group 2: patients receiving l-carnitine plus supervised exercise plan. group 3: patients receiving placebo and supervised exercise plan. all three groups will be evaluated for functional and anthropometric parameters: prior, during and after intervention. in addition, the dosage of l-carnitine and acetylcarnitine will be evaluated before and after the intervention.

Eligibility criteria:
inclusion criteria: * patients who meet at least 2 criteria for the fragility phenotype of linda fried * ability to comply with aerobic physical activity of moderate intensity and basic resistance. * not depressed patients (yesavage \<5 in patients without previous depression or hamilton \<7 in patients in treatment for depression) * mmse (mini-mental state examination) greater than 24 points. * independent or mildly dependent patients, barthel\> 95 points. * patients without visual disturbances or with decreased visual acuity corrected. * no pain or with vas (visual analogue scale) \<3/10. * patients without nutritional risk, mna (mini nutritional assessment \> 23.5 / 30 points) and bmi (body mass index) \> 23 kg / m2. exclusion criteria: * absolute contraindications for performing physical exercise: recent ami or unstable angina, uncontrolled hypertension, acute hf and complete av block. * patients with osteoarticular pathology that limits their physical activity. * previous neurological pathology (stroke, enf. of parkinson's). * acute or chronic diseases decompensated or with lymphedema that makes difficult the accomplishment of the bioimpedanciometry. * patients using orthopedic devices and prostheses or pacemakers that interfere with gait or impede the achievement of bioimpedanciometry. * bmi less than 23 and / or an involuntary weight loss of 3kg or more in the last 3 months. * psychiatric disorders that hinder adherence to treatment. * moderate to severe chronic renal disease * patient who does not agree to participate in the study.

Keywords: carnitine elderly functional status
hes patch versus blood patch

Conditions: Intracranial Hypotension

Summary: the injection of autologous blood blood patch (bp) into the epidural space is the standard treatment for headache associated with intracranial hypotension. it provokes cerebral vasoconstriction. it is cons-indicated in a number of situations (hiv positive, fever, sepsis, leukemia). the purpose of this study is to evaluate another technique using a patch made by injecting an epidural hydroxyethylstarch solution (hes 130, 0.4, 6%) instead of blood patch. this alternative technique is simple to implement and does not have some of the specific blood pressure contra-indications. the study aims at comparing the "blood patch" group versus the "hes patch" in terms of clinical efficacy , tolerance, satisfaction of the anesthetist, ease of implementation and effect of the injection of epidural anesthesia on cerebral blood flow within 24 hours.


Eligibility criteria:
inclusion criteria: * subjects older than 18 years.· * subjects with an intracranial hypertension syndrome secondary to an epidural, spinal or lumbar puncture (and therefore presumed iatrogenic) with a sub arachnoid space or subjects with intracranial hypertension syndrome of primitive origin requiring treatment with epidural patch · * subjects with a temporal window of sufficient quality to carry out the transcranial doppler · * subjects haven read the informed consent, signed and dated prior to the start of any proceedings related to the tial· * subjects affiliated to health insurance· * subjects having been informed of the results of a prior medical consultation exclusion criteria: * subjects with a cons-indication to an epidural patch: * blood disorders constitutional or acquired coagulation with platelets * subjects under treatment with curative doses of antiplatelet drugs or anticoagulants * subjects under shock and / or hypovolemia * subjects under generalized sepsis or at the puncture site * any other cons-indication to performing an epidural
a long-term follow-up study of participants treated with a2 biotherapeutics (a2 bio) gene therapy (gt) products

Conditions: Solid Tumor Cancer; Solid Tumor, Unspecified, Adult; Colorectal Carcinoma; Colorectal Carcinoma (CRC); Non Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); Pancreatic Cancer; NSCLC; Mesothelioma; Ovarian Cancer; Ovarian Carcinoma; Head and Neck (HNSCC); Head and Neck Cancer; Renal Cell Carcinoma (Kidney Cancer); Triple Negative Breast Cancer (TNBC)

Summary: this protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received a2 bio gene therapy (gt) products.

this is a long-term follow-up study designed to evaluate delayed safety events and long-term efficacy of a2 bio gt products for participants who received any amount of a2 bio gt products in a previous interventional study. no further interventional treatment is administered in this study. participants will enroll in this long-term follow-up study upon completion of 2 years of follow-up in the assigned interventional study in which they received treatment. participants will be followed for up to 15 years after administration of a2 bio gt product. this study will collect long-term safety and efficacy data as outlined by the fda guidance for long-term follow-up for gt products.

Eligibility criteria:
inclusion criteria: 1. received any amount of a2 bio gt product on a previous a2 bio interventional study 2. able to provide written informed consent for this long-term follow-up study 3. able to comply with study requirements exclusion criteria: 1. there are no specific exclusion criteria for this study

Keywords: car t cell therapy gene therapy
supportive treatment of severe heart failure by renal denervation

Conditions: Heart Failure

Summary: the overactivity of sympathetic nervous system is worsening the hemodynamic state of heart failure patients. the present study is planned to reduce the sympathetic tone in patients with severe heart failure by renal nervous denervation.

the patient population consists of heart failure patients who are not responding properly to medication and biventricular pacing therapy. the inappropriate response to these therapies is evaluated by patient history (nyha iii-iv), echocardiography (ef \< 45%), 6-minute walking test (\<440m) and measurements of p-probnp. the patients who fulfill the inclusion criteria will undergo renal nervous denervation. the patients will be followed up with the same methods as they were recruited to the study (by patient history (nyha iii-iv), echocardiography (ef \< 45%), 6-minute walking test (\<440m) and measurements of p-probnp). the overall time of follow-up will be 24 months. the patients are randomised according to the waiting list principle in a manner to 1:1. the waiting time will be 6 months.

Eligibility criteria:
inclusion criteria: * nyha iii-iv * ejection fraction \<45 % * 6-minute walking test under 440m exclusion criteria: * unstable hemodynamic state * uncooperation

Keywords: renal nervous denervation
the effect of topical anesthetics on patients' pain and operative experience during treatment with qswitched laser

Conditions: Lentigo

Summary: this study will conduct a split-face and -body randomized control trial to compare lidocaine 2.5%/prilocaine 2.5% topical anesthetic (lpta), lidocaine 7%/tetracaine 7% topical anesthetic (ltta), and placebo vechicle (pv) on patients' pain perceptions with q-switched 532nm laser for the treatment of lentigines and/or photorejuvenation.subjects will fill out a pain score on a visual analog scale (vas) with 0 being no pain and 10 being most pain after each treatment area is completed.


Eligibility criteria:
inclusion criteria: 1. patients who have moderate lentigines and/or photodamage and desire laser toning. 2. females 25-65 years of age. 3. in good health. 4. have fitzpatrick phototype i-iii. 5. willingness and the ability to understand and provide informed consent and communicate with the investigator/study staff. exclusion criteria: 1. younger than 25 or older than 65 years of age. 2. pregnant or lactating. 3. is a male. 4. has received the following treatments on the face: * ablative or non-ablative laser procedure in the past 3 months * radiofrequency device treatment in the past 3 months * ultrasound device treatment in the past 3 months * medium to deep chemical peel in the past 3 months 5. has an active infection on the face or upper inner arms (excluding mild acne). 6. is allergic to lidocaine, tetracaine, or prilocaine. 7. has kidney disease and/or liver disease. 8. has g-6-pd and/or pseudocholinesterase deficiency. 9. is taking a class i anti-arrhythmic medication. 10. is tanned. 11. has a history of hyperpigmentation with laser treatment. 12. has a mental illness. 13. has a history of a chronic pain condition such as fibromyalgia or vulvodynia. 14. unable to understand the protocol or to give informed consent. 15. multiply recurrent episodes of cold sores. 16. any significant skin disease beyond mild acne. 17. any other condition that would, in the professional opinion of the investigator, potentially affect response or participation in the clinical clinical study, or would pose as an unacceptable risk to the subject.
study assessing pti-428 safety, tolerability, and pharmacokinetics in subjects with cystic fibrosis on kalydeco® as background therapy

Conditions: Cystic Fibrosis

Summary: the trial will consist of a single treatment group enrolling adult subjects with cf on background therapy with kalydeco®. approximately 16 subjects will be enrolled.

the single treatment group will enroll adult subjects with cf currently on stable kalydeco® background therapy for a minimum of 3 months at the time of randomization. subjects will be randomized to either pti-428 or placebo. each dose will be administered once daily (qd) for a total of 14 days. the subjects will continue treatment with kalydeco® throughout the study.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cf. * stable on kalydeco dosing for both label indication and per label dosing for a minimum of 3 months at the time of randomization * forced expiratory volume in 1 second (fev1) 40-90% predicted. * non-smoker and non-tobacco user for a minimum of 30 days prior to screening and for the duration of the study. exclusion criteria: * participation in another clinical trial or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, prior to study day 1. * history of cancer within the past five years (excluding cervical cis with curative therapy for at least one year prior to screening and non-melanoma skin cancer). * history of organ transplantation. * any sinopulmonary infection or cf exacerbation requiring a change or addition of medication (including antibiotics) within 1 month of study day 1 or any other clinically significant infection as determined by the investigator within 1 month of day 1. * history of alcohol or drug abuse or dependence within 12 months of screening as determined by the investigator. * male and female of child-bearing potential, unless they are using highly effective methods of contraception during participation in the clinical study and for 4 weeks after termination from study. * pregnant or nursing women.